Skip to content
Study details
Enrolling now

Phage Treatment for Cystic Fibrosis Lung Infection

BiomX Ltd
NCT IDNCT06998043ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

63

Study length

about 1.2 years

Ages

18+

Locations

14 sites in AK, AL, AR +7

What this study is about

Researchers are testing whether nebulized phage (BX004) can treat chronic Pseudomonas aeruginosa lung infection in people with cystic fibrosis. The trial will last 455 days and involve comparing BX004 to a placebo, along with their usual CF treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Receive BX004

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change from Baseline in CFQ-R respiratory domain, Change from Baseline in CFRSD-CRISS, Incidence of treatment-emergent adverse events [safety and tolerability]

Body systems

Infectious, Respiratory